CTSK and asthma: Odanacatib, a Cathepsin K inhibitor, reduces EMTU activation and exhibits efficacy in animal asthma models. However, its development for osteoporosis was discontinued due to cardiovascular and cerebrovascular adverse effects, highlighting the necessity for safety considerations in future development